Allergan reports $1.53 billion in product net sales for third quarter
Allergan reported $1.53 billion in total product net sales for the third quarter, an increase of 12.9% over the third quarter 2012, according to a press release.
Total specialty pharmaceuticals net sales increased 12.8% compared with the third quarter of 2012, and total medical devices net sales increased 13.4%.
Quarterly diluted earnings per share attributable to stockholders totaled $1.10, up from $0.82 reported for the same period last year. Non-GAAP diluted earnings per share attributable to stockholders totaled $1.23, up from $1.04 a year ago.
For the full year, Allergan expects total product net sales to be between $6.1 billion and $6.2 billion, excluding the obesity intervention business.
The board of directors declared a third-quarter dividend of $0.05 per share, payable on Dec. 11 to stockholders of record on Nov. 20.